

AMENDMENTS

IN THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claims 1-9, 12-19, 27-38 are pending in this Application.

Claims 24-30 are withdrawn from consideration but are subject to rejoinder.

Claims 1, 8, 9, 12, and 13 are currently amended.


Claims 2-7, 18, 19, and 27-38 are currently cancelled.

Claims 10, 11, 20, 21, 22, and 23 were previously cancelled.

Claims 14, 15, 16, and 17 were previously presented.

Claims 39-53 are new.

1. (**currently amended**) A compound represented by formula I,



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof, and wherein,

each W is ~~independently N or~~ CR¹;

each R¹ is independently selected from -H, ~~halogen, trihaloalkyl, CN, NH₂, NO₂, OR⁶, N=CNR⁶R⁷, N(R⁶)C(=NR⁸)NR⁶R⁷, SR⁶, S(O)₁₋₂R⁶, SO₂NR⁶R⁷, CO₂R⁶, C(O)NR⁶R⁷, C(O)N(OR⁶)R⁷, C(=NR⁸)NR⁶R⁷, N(R⁶)SO₂R⁷, C(O)R⁷, R⁷, and -A-R⁷~~; provided at least one of R¹ is -A-R⁷ and is located at the 5-position of the indolinone ring, wherein, only for said at least one -A-R⁷, R⁷ must be an heterocyclic ring piperidin-4-yl, and any

~~nitrogen of said optionally substituted heterocyclic ring cannot be directly bound to A,~~
and where the nitrogen of the heterocyclic ring piperidin-4-yl of $-A-R^7$ is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, ~~alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, and sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;~~

A is O , $S(O)_{0-2}$, and NR^6NH ;

L is O , $S(O)_{0-2}$, or NR^3 ;

Q is C or N, when Q is N, then R^4 does not exist;

R^2 and R^3 are each independently $-H$ or $-R^7$;

R^4 and R^5 are each independently selected from $-H$, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, $-CN$, $-NO_2$, $-NH_2$, halogen, trihalomethyl, and $-R^7$; or

R^4 and R^5 , when taken together, form a ~~five or~~ six-membered aromatic ring system containing ~~between zero and two~~ nitrogens, said ~~five or~~ six-membered aromatic ring system is optionally substituted with between zero and four of R^{15} ;


R^6 is selected from $-H$, C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocycl C_{1-8} alkyl, aryl, and heterocycl;

R^7 , for other than R^7 in $-A-R^7$, is selected from $-H$, C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocycl C_{1-8} alkyl, aryl, and heterocycl; provided that there are at least two carbons between any heteroatom of R^7 and either nitrogen to which R^2 and R^3 are attached; or

~~R^6 and R^7 , when taken together with a common nitrogen to which they are attached, form a five to seven membered heterocyclic ring, said five to seven membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;~~

R^8 is $-H$, $-NO_2$, $-CN$, $-OR^6$, and C_{1-8} alkyl;

X is selected from one of the following six formulae:



wherein m is zero to five, n is zero to three, and Z is N or CR¹⁰;

R¹⁰ is selected from -H, halogen, trihalomethyl, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷;


K is O, S, or NR¹¹; and

R¹¹ is selected from cyano, -NO₂, -OR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(O)R⁷, and R⁶; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷.

Claims 2-7 (cancelled)


8. (currently amended) The compound according to ~~claim 7~~claim 1, wherein X is



m is 0 to 3, and R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and -C₁₋₈alkyl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of

diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. (currently amended) A compound of formula II:



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A is selected from O, $S(O)_{0-4}$, and NR^6NH ;

R^7 , in $-A-R^7$, is selected from ~~perhydroazepinyl, piperidinyl, piperidin-4-yl and is located on the 5-position of the indolinone ring pyrrolidinyl, and azetidine~~; wherein the ring nitrogen of R^7 is substituted with a group R^{12} ; and

R^{12} is selected from a) -H, b) C_{1-8} alkyl, c) $-SO_2R^6$, d) $-SO_2NR^6R^7$, e) $-CO_2R^6$, f) $-C(O)NR^6R^7$, and g) $-C(O)R^7$, ~~and h) three or four carbon bridge between the ring nitrogen of R^7 and a carbon vicinal to the ring nitrogen of R^7 ; said three or four atom bridge optionally containing an oxygen in substitution for a carbon of the bridge~~; and

where the C_{1-8} alkyl in b) ~~and the bridge in h)~~ are optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, ~~methylenedioxy~~, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;

R^6 is selected from -H and C_{1-8} alkyl;

R^4 and R^5 are each independently selected from -H, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, -CN, -NO₂, -NH₂, halogen, trihalomethyl, and -R⁷; or

R^4 and R^5 , when taken together, form a ~~five or~~ six-membered aromatic ring system containing ~~between zero and two~~ nitrogens, said ~~five or~~ six-membered aromatic ring system is optionally substituted with between zero and four of R¹⁵;

R¹⁰ is selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and C₁₋₈alkyl; m is 0 to 3;


R⁷, for other than R⁷ in A-R⁷, is selected from -H, C₁₋₈alkyl, arylC₁₋₈alkyl, heterocyclylC₁₋₈alkyl, aryl, and heterocyclyl;

R⁸ is -H, -NO₂, -CN, -OR⁶, and C₁₋₈alkyl; and

each R¹⁵ is independently selected from -H, halogen, -NH₂, -NO₂, -OR⁶, -N=CNR⁶R⁷, -NR⁶R⁷, -N(R⁶)C(=NR⁸)NR⁶R⁷, -SR⁶, -S(O)₁₋₂R⁶, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -C(O)N(OR⁶)R⁷, -C(=NR⁸)NR⁶R⁷, -N(R⁶)SO₂R⁶, -C(O)R⁷, and R⁷.

Claims 10-11 (previously canceled)

12. (currently amended) A compound according to formula III.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

R¹² is a C₁₋₄alkylene;

R^{13} is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, and an heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, dialkylamino group, and heteroalicyclic cannot be attached to a carbon of R^{12} which is directly attached to the ring nitrogen of the piperidine in formula III;
 R^4 and R^5 are each independently selected from -H, $-OR^6$, $-NR^6R^7$, $-S(O)_{0-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, -CN, $-NO_2$, $-NH_2$, halogen, trihalomethyl, and $-R^7$; or

R^4 and R^5 , when taken together, form a ~~five or~~ six-membered aromatic ring system containing ~~between zero and two~~ nitrogens, said ~~five or~~ six-membered aromatic ring system is optionally substituted with between zero and four of R^{15} ;

R^6 is selected from -H and C_{1-8} alkyl;

R^7 is selected from -H, C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocyclyl C_{1-8} alkyl, aryl, and heterocyclyl;


R^8 is -H, $-NO_2$, -CN, $-OR^6$, and C_{1-8} alkyl;

R^{10} is selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and C_{1-8} alkyl;

m is 0 to 3; and

each R^{15} is independently selected from -H, halogen, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$, and R^7 .

13. **(currently amended)** A compound according to formula **IIIa**,



IIIa

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein R^{12} is a C_{2-4} alkylene;

R^{13} is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group and an heteroalicyclic;

R^{10} is selected from -H, halogen, perfluoroalkyl, $-NH_2$, $-NO_2$, $-OR^6$, $-N=CNR^6R^7$, $-NR^6R^7$, $-N(R^6)C(=NR^8)NR^6R^7$, $-SR^6$, $-S(O)_{1-2}R^6$, $-SO_2NR^6R^7$, $-CO_2R^6$, $-C(O)NR^6R^7$, $-C(O)N(OR^6)R^7$, $-C(=NR^8)NR^6R^7$, $-N(R^6)SO_2R^6$, $-C(O)R^7$;

R^4 and R^5 are each independently selected from -H, halogen, and C_{1-4} alkyl; or R^4 and R^5 combined are a phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, heterocyclalkyl, heterocycl, alkoxy, substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino, aryloxy, arylalkyloxy, carboxy, acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, ~~oxo~~-carbamyl, and acylamino; m is 0-3;

R^6 is selected from -H and C_{1-8} alkyl, said C_{1-8} alkyl substituted with at least one of $-CO_2H$ and $-CO_2C_{1-8}$ alkyl;

R^7 is selected from -H, C_{1-8} alkyl, aryl C_{1-8} alkyl, heterocycl C_{1-8} alkyl, aryl, and heterocycl;

R^8 is -H, $-NO_2$, -CN, $-OR^6$, and C_{1-8} alkyl.

14. **(previously presented)** The compound according to claim 13, wherein R^{12} is an ethylene; R^{10} is halogen; R^4 and R^5 are each independently selected from -H, halogen, and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

15. **(previously presented)** The compound according to claim 14, wherein each R^{10} is independently selected from fluorine and chlorine; R^4 and R^5 are each independently selected from -H and C_{1-2} alkyl; and m is 1-3; or a single stereoisomer, a single geometric

isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(previously presented)** The compound according to claim 15, wherein each R¹⁰ is independently selected from fluorine and chlorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

17. **(previously presented)** The compound according to claim 16, wherein R¹⁰ is fluorine; R⁴ and R⁵ are each independently selected from -H and -CH₃; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

18. **(currently canceled)**

19. **(currently canceled)**

Claims 20-23 **(previously cancelled)**

24. **(currently canceled)**

25. **(previously canceled)**

26. **(previously canceled)**

Claims 27-38 **(currently canceled)**

39. **(new)** The compound according to claim 17, selected from:

49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one;
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{{1-(2-piperidin-1-ylethyl)piperidin-4-yl}amino}-1,3-dihydro-2H-indol-2-one;
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{{1-(2-morpholin-4-ylethyl)piperidin-4-yl}amino}-1,3-dihydro-2H-indol-2-one;

84	(3Z)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl}amino)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one;
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; and
113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

40. (new) The Compound of Claim 9 selected from

22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one;
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one;
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one; and
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

41. (new) The compound of Claim 12 selected from

1	(3Z)-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-{[1-(phenylmethyl)pyrrolidin-3-yl]amino}-1,3-dihydro-2H-indol-2-one;
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione;
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;

59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
88	ethyl 2-{{(Z)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl}-4-methyl-1H-imidazole-5-carboxylate};
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one; and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

42. (new) The compound of Claim 13 selected from

3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{{5-(methyloxy)-1H-benzimidazol-2-yl}[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
8	(3Z)-3-{1H-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1 <i>H</i> -imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2 <i>H</i> -indol-2-one;
16	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
17	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
18	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
19	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
21	(3Z)-3-[(3-aminophenyl)(1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
23	3-((Z)-1 <i>H</i> -benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3 <i>H</i> -indol-3-ylidene)methyl)benzenecarboximidamide;
24	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
26	(3Z)-3-{1 <i>H</i> -benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
27	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
29	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
38	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
39	(3Z)-3-{1 <i>H</i> -benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
45	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
46	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
47	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
55	(3Z)-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
56	(3Z)-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1 <i>H</i> -imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2 <i>H</i> -indol-2-one;
61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;

71	(3Z)-3-{1 <i>H</i> -imidazol-2-yl}[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
72	(3Z)-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
89	(3Z)-3-[1 <i>H</i> -imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
90	(3Z)-3-{1 <i>H</i> -imidazol-2-yl}[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1 <i>H</i> -imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
114	(3Z)-3-[(3-trifluoromethylphenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one; and
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;

where the compound is optionally as a pharmaceutically acceptable salt thereof.

43. **(new)** The compound of Claim 16 selected from

40	(3Z)-3-[(3-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
41	(3Z)-3-[(3-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
42	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
48	(3Z)-3-[(3-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
54	(3Z)-3-[(3,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
66	(3Z)-3-[(4-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one

73	(3Z)-3-[(3,5-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
75	(3Z)-3-[(3,5-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
79	(3Z)-3-[(3,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
91	(3Z)-3-[(4-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
109	(3Z)-3-[(2,3-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
112	(3Z)-3-[(2,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one

where the compound is optionally as a pharmaceutically acceptable salt thereof.

44. **(new)** The compound of Claim 39 named (3Z)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

45. **(new)** The compound of Claim 39 named (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

46. **(new)** The Compound of Claim 1 selected from (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl}[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-

dihydro-2*H*-indol-2-one and (3*Z*)-3-{1*H*-imidazol-2-yl}[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2*H*-indol-2-one; or a single geometric isomer thereof, optionally as a pharmaceutically acceptable salt thereof. 47. **(new)** A pharmaceutical composition comprising a compound according to Claim 1, 9, 12, 13, 39, 40, 41, 42, 43, or 46 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

48. **(new)** A pharmaceutical composition comprising a compound according to Claim 44 or 45, where the compound is optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.